Expression and Clinical Significance of mPGES-1 and NF-κB p65 in Diffuse Large B Cell Lymphoma
- VernacularTitle:mPGES-1、NF-κB p65在弥漫大B细胞淋巴瘤中的表达及临床意义
- Author:
Zhi-Yuan HE
1
;
Shuang-Feng XIE
;
Da-Nian NIE
;
Song-Mei YIN
;
Zhang-Hai HE
;
Jie XIAO
;
Li-Ping MA
;
Yi-Qing LI
Author Information
1. 中山大学孙逸仙纪念医院血液内科
- Keywords:
microsomal prostaglandin E synthase-1;
nuclear transcription factor kappa B p65;
diffuse large B-cell lymphoma;
clinical significance;
prognosis
- From:
Journal of Sun Yat-sen University(Medical Sciences)
2018;39(1):73-81
- CountryChina
- Language:Chinese
-
Abstract:
[Objective]Examine the expression of microsomal prostaglandin E synthase-1(mPGES-1)and nuclear transcription factor kappa B p65(NF-κB p65)in diffuse large B cell lymphoma(DLBCL),assessing their correlation with clinical variables,prognosis and potential clinical valve.[Methods]The immunohistochemistry was uesd to investigate the expression of mPGES-1 and NF-κB p65 in 83 DLBCL patiens'tissues.The relationship between these two proteins and the clinical variables and prognosis of these patients was evaluated.[Results]The high expression of mPGES-1 and NF-κB p65 were observed in 65.1%(54/83)and 73.5%(61/83)cases of DLBCL,respectively.The expression level of NF-κB p65 was positively correlated with mPGES-1 expression(P<0.05).The expression of these two proteins was found to be significantly associated with B cell lymphoma/leukemia-2 protein(BCL-2),higher expression of Ki67,higher lactate dehydrogenase (LDH),more extranodal lesions,advanced Ann Arbor stage and higher international prognostic index(IPI)score(P<0.05). In addition,NF-κB p65 was related with multiple myeloma oncogene 1(MUM1),pathological type(P<0.05). Both mPGES-1 and NF-κB p65 overexpression was correlated with worse overall survival(OS)while NF-κB p65 was an in-dependent prognostic factor for OS of DLBCL(P<0.05).[Conclusions]mPGES-1 and NF-κB p65 were highly expressed in DLBCL and closely linked with each other. The overexpression of mPGES-1 and NF-κB p65 was correlated with tumor progression and unfavorable prognosis in patients with DLBCL.
